Garrison Asset Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $627K | Sell |
4,023
-12
| -0.3% | -$1.94K | 0.32% | 62 |
|
|
2024
Q2 | $629K | Sell |
4,035
-10
| -0.2% | -$1.5K | 0.33% | 60 |
|
|
2024
Q1 | $548K | Hold |
4,045
| – | – | 0.29% | 62 |
|
|
2023
Q4 | $545K | Hold |
4,045
| – | – | 0.3% | 63 |
|
|
2023
Q3 | $548K | Sell |
4,045
-110
| -3% | -$15K | 0.33% | 60 |
|
|
2023
Q2 | $595K | Sell |
4,155
-76
| -2% | -$11.2K | 0.36% | 58 |
|
|
2023
Q1 | $587K | Sell |
4,231
-80
| -2% | -$10.8K | 0.36% | 58 |
|
|
2022
Q4 | $585K | Sell |
4,311
-50
| -1% | -$6.27K | 0.38% | 58 |
|
|
2022
Q3 | $478K | Sell |
4,361
-12
| -0.3% | -$1.52K | 0.34% | 62 |
|
|
2022
Q2 | $578K | Sell |
4,373
-67
| -2% | -$8.79K | 0.39% | 60 |
|
|
2022
Q1 | $589K | Sell |
4,440
-8
| -0.2% | -$959 | 0.33% | 62 |
|
|
2021
Q4 | $518K | Buy |
4,448
+18
| +0.4% | +$2.12K | 0.28% | 65 |
|
|
2021
Q3 | $532K | Sell |
4,430
-58
| -1% | -$6.75K | 0.32% | 62 |
|
|
2021
Q2 | $538K | Sell |
4,488
-24
| -0.5% | -$2.63K | 0.33% | 62 |
|
|
2021
Q1 | $449K | Buy |
4,512
+434
| +11% | +$43.6K | 0.29% | 68 |
|
|
2020
Q4 | $408K | Sell |
4,078
-6,381
| -61% | -$676K | 0.28% | 62 |
|
|
2020
Q3 | $1.15M | Sell |
10,459
-66
| -0.6% | -$7.34K | 0.6% | 46 |
|
|
2020
Q2 | $1.11M | Sell |
10,525
-265
| -2% | -$27.4K | 0.63% | 45 |
|
|
2020
Q1 | $964K | Sell |
10,790
-810
| -7% | -$76.3K | 0.65% | 44 |
|
|
2019
Q4 | $1.16M | Sell |
11,600
-362
| -3% | -$34.1K | 0.57% | 47 |
|
|
2019
Q3 | $1.07M | Sell |
11,962
-136
| -1% | -$11.8K | 0.55% | 47 |
|
|
2019
Q2 | $999K | Sell |
12,098
-65
| -0.5% | -$5.1K | 0.52% | 47 |
|
|
2019
Q1 | $984K | Buy |
12,163
+117
| +1% | +$9.22K | 0.52% | 49 |
|
|
2018
Q4 | $915K | Sell |
12,046
-147
| -1% | -$11.5K | 0.54% | 48 |
|
|
2018
Q3 | $965K | Buy |
12,193
+277
| +2% | +$21K | 0.48% | 50 |
|
|
2018
Q2 | $837K | Buy |
11,916
+2,631
| +28% | +$189K | 0.42% | 51 |
|
|
2018
Q1 | $649K | Hold |
9,285
| – | – | 0.36% | 53 |
|
|
2017
Q4 | $644K | Buy |
9,285
+191
| +2% | +$12.9K | 0.34% | 59 |
|
|
2017
Q3 | $616K | Buy |
9,094
+65
| +0.7% | +$4.11K | 0.35% | 60 |
|
|
2017
Q2 | $616K | Buy |
9,029
+43
| +0.5% | +$2.81K | 0.36% | 57 |
|
|
2017
Q1 | $560K | Sell |
8,986
-80
| -0.9% | -$4.66K | 0.33% | 61 |
|
|
2016
Q4 | $495K | Sell |
9,066
-430
| -5% | -$24.4K | 0.31% | 63 |
|
|
2016
Q3 | $624K | Hold |
9,496
| – | – | 0.4% | 56 |
|
|
2016
Q2 | $573K | Buy |
9,496
+102
| +1% | +$5.92K | 0.38% | 56 |
|
|
2016
Q1 | $529K | Buy |
9,394
+375
| +4% | +$22.5K | 0.37% | 57 |
|
|
2015
Q4 | $612K | Buy |
9,019
+510
| +6% | +$33.4K | 0.42% | 56 |
|
|
2015
Q3 | $541K | Buy |
8,509
+13
| +0.2% | +$855 | 0.39% | 56 |
|
|
2015
Q2 | $541K | Sell |
8,496
-110
| -1% | -$7.53K | 0.36% | 59 |
|
|
2015
Q1 | $589K | Buy |
8,606
+273
| +3% | +$19K | 0.39% | 55 |
|
|
2014
Q4 | $595K | Hold |
8,333
| – | – | 0.45% | 49 |
|
|
2014
Q3 | $595K | Sell |
8,333
-129
| -2% | -$9.44K | 0.45% | 49 |
|
|
2014
Q2 | $629K | Sell |
8,462
-50
| -0.6% | -$3.62K | 0.45% | 52 |
|
|
2014
Q1 | $552K | Buy |
8,512
+224
| +3% | +$14.5K | 0.43% | 51 |
|
|
2013
Q4 | $492K | Buy |
8,288
+560
| +7% | +$30.4K | 0.4% | 51 |
|
|
2013
Q3 | $401K | Buy |
7,728
+87
| +1% | +$4.37K | 0.35% | 52 |
|
|
2013
Q2 | $361K | Buy |
+7,641
| New | +$389K | 0.34% | 55 |
|
Other funds holding AZN
Garrison Asset Management's AZN Position: Q3 2024 in Review
Garrison Asset Management reduced its AstraZeneca (AZN) stake by 0.3% in Q3 2024, selling an estimated $1.94K and leaving 4,023 shares worth $627K. The position accounts for 0.32% of the portfolio, ranked #62.
Garrison Asset Management first reported a position in AZN in Q2 2013 and has held it in 46 quarters since. The position peaked at $1.16M in Q4 2019. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.
- Garrison Asset Management held 4,023 shares of AstraZeneca worth $627K as of Q3 2024.
- Garrison Asset Management sold 12 AstraZeneca shares in Q3 2024, an estimated $1.94K.
- AstraZeneca made up 0.32% of Garrison Asset Management's portfolio in Q3 2024, its #62 holding.
- Garrison Asset Management first reported a position in AstraZeneca in Q2 2013 and has held it in 46 quarters since.
- Garrison Asset Management's AstraZeneca position peaked at $1.16M in Q4 2019.
- 1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.
Based on Garrison Asset Management's 13F filing for Q3 2024, filed 30 Oct 2024.